Research programme: phosphodiesterase IV inhibitors - CJ Corporation
Alternative Names: PDE4 inhibitors research programme - CJ CorporationLatest Information Update: 07 Dec 2006
At a glance
- Originator CJ Corporation
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 23 Dec 2002 Cheil Jedang is now called CJ Corporation
- 23 Jun 2000 Preclinical development for Asthma in South Korea (PO)